StemCells (STEM) PT Cut to $3 at Maxim Group

Go back to StemCells (STEM) PT Cut to $3 at Maxim Group

StemCells, Inc. Announces Strategic Realignment

December 23, 2015 8:05 AM UTC

NEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ: STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Companys resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).

Evidence of efficacy from the Companys ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function previously considered unrecoverable. StemCells recently reported a pattern of improvements in both... More